drugset
drugset / Trial / NCT06717438

Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])

NCT06717438 ↗

Phase 2 Active not recruiting 30 enrolled Shionogi
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objective of this study is to assess the efficacy, safety, and tolerability of BPN14770 in participants aged 9 to 45 years with JS.

Timeline

Start
2025-05-13
Primary completion
2027-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject zatolmilast Small molecule — Oral

Indications

No indication recorded.